EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

Hidetoshi Shimizu iD, Michael A Tortorici, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, Kanami Sugimoto-Kawabata, Mattheus Thijs van Iersel, Jan Jaap van Lier, Stephen Djedjos und 2 weitere

Clinical and Translational Science · 2024-08 · 17 (8)

DOI: 10.1111/cts.70000 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 16.08.2024. Verfasst von Hidetoshi Shimizu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Group, Data Science Department, Ikuyaku, Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Ja…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP11B2, Aldosterone, Dose-Response Relationship, Drug. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysregulation of the mineralocorticoid hormone aldosterone is an increasingly prevalent cause of hypertension. Aldosterone synthase (CYP11B2) shares 93% homology to 11β‐hydroxylase (CYP11B1), which produces cortisol. Lorundrostat, a highly selective inhibitor of CYP11B2, is a potential safe and effective treatment for aldosterone‐dependent, uncontrolled hypertension, including treatment‐resistant hypertension. Lorundrostat showed highly selective inhibition of CYP11B2 in vitro, with 374‐fold selectivity for CYP11B2 vs. CYP11B1. A first‐in‐human study of single ascending doses ranging from 5 to 800 mg and multiple ascending doses ranging from 40 to 360 mg once daily was conducted in healthy participants. After single‐ and multiple‐dose administration, lorundrostat plasma levels peaked 1–3 h after administration with a t 1/2 of 10–12 h. Plasma aldosterone decreased up to 40% with single 100‐mg to 200‐mg doses and up to 70% with single 400 to 800‐mg doses. Plasma aldosterone returned to baseline within 16 h after single 100‐mg doses and multiple once‐daily 120‐mg doses. Lorundrostat demonstrated a favorable safety profile in healthy participants. Dose‐ and exposure‐dependent inhibition of renal tubular sodium reabsorption was observed across a clinically relevant dose range with no suppression of basal or cosyntropin‐stimulated cortisol production and only a modest increase in mean serum potassium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP11B2AldosteroneDose-Response Relationship, DrugHumansMaleAdultFemaleMiddle AgedYoung AdultHealthy VolunteersEnzyme InhibitorsDouble-Blind MethodAdolescent

Substanzen

Cytochrome P-450 CYP11B2AldosteroneEnzyme Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology Group, Data Science Department, Ikuyaku, Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Mineralys Therapeutics, Radnor, Pennsylvania, USA.
  • Clinical Research & Development II, Ikuyaku, Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Clinical Department, Mitsubishi Tanabe Pharma Corporation, London, UK.
  • Research Unit/Neuroscience, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan.
  • Translational Research, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.

ORCID-Profile: Hidetoshi Shimizu

Zitieren

APA

Shimizu, H., Tortorici, M. A., Ohta, Y., Ogawa, K., Rahman, S. M. A., Fujii, A., Hiraga, Y., Kawai, M., Sugimoto-Kawabata, K., van Iersel, M. T., van Lier, J. J., Djedjos, S., Slingsby, B. T., & Rodman, D. M. (2024). First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.70000

Vancouver

Shimizu H, Tortorici MA, Ohta Y, Ogawa K, Rahman SMA, Fujii A, et al. First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.70000

BibTeX
@article{Shimizu2024,
  author = {Shimizu, Hidetoshi and Tortorici, Michael A and Ohta, Yoshiyasu and Ogawa, Kei and Rahman, Sheikh Mohammed Ashfaq and Fujii, Aya and Hiraga, Yuki and Kawai, Mizue and Sugimoto-Kawabata, Kanami and van Iersel, Mattheus Thijs and van Lier, Jan Jaap and Djedjos, Stephen and Slingsby, B T and Rodman, David M},
  title = {First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1111/cts.70000}
}
Kostenlos starten →